0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Biosimilars Market Research Report 2024
Published Date: January 2024
|
Report Code: QYRE-Auto-25I8440
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Biosimilars Market Insights and Forecast to 2028
BUY CHAPTERS

Global Biosimilars Market Research Report 2024

Code: QYRE-Auto-25I8440
Report
January 2024
Pages:111
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Biosimilars Market Size

The global Biosimilars market was valued at US$ 5727.5 million in 2023 and is anticipated to reach US$ 18790 million by 2030, witnessing a CAGR of 18.0% during the forecast period 2024-2030.

Biosimilars Market

Biosimilars Market

A biosimilar is a biologic medical product highly similar to another already approved biological medicine (the 'reference medicine'). Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilars.

Report Scope

The Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Biosimilars Market Report

Report Metric Details
Report Name Biosimilars Market
Accounted market size in 2023 US$ 5727.5 million
Forecasted market size in 2030 US$ 18790 million
CAGR 18.0%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
  • Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
  • Recombinant Glycosylated Proteins
Segment by Application
  • Oncology
  • Blood Disorders
  • Growth Hormonal Deficiency
  • Chronic and Autoimmune Disorders
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Pfizer, Novartis, Biocon, Biogen, Fresenius Kabi AG, Boehringer Ingelheim, Merck KgaA, Mylan, Eli Lilly, Teva Pharmaceutical, Dr. Reddy's Laboratories, Amgen, Celltrion, Samsung Biologics, Roche, Probiomed, Apotex, Chong Kun Dang, JCR Pharmaceuticals, Gan & Lee Pharmaceuticals, Gedeon Richter, Biocad, Coherus Bioscience, Stada Arzneimittel AG
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Biosimilars Market growing?

Ans: The Biosimilars Market witnessing a CAGR of 18.0% during the forecast period 2024-2030.

What is the Biosimilars Market size in 2030?

Ans: The Biosimilars Market size in 2030 will be US$ 18790 million.

Who are the main players in the Biosimilars Market report?

Ans: The main players in the Biosimilars Market are Pfizer, Novartis, Biocon, Biogen, Fresenius Kabi AG, Boehringer Ingelheim, Merck KgaA, Mylan, Eli Lilly, Teva Pharmaceutical, Dr. Reddy's Laboratories, Amgen, Celltrion, Samsung Biologics, Roche, Probiomed, Apotex, Chong Kun Dang, JCR Pharmaceuticals, Gan & Lee Pharmaceuticals, Gedeon Richter, Biocad, Coherus Bioscience, Stada Arzneimittel AG

What are the Application segmentation covered in the Biosimilars Market report?

Ans: The Applications covered in the Biosimilars Market report are Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Others

What are the Type segmentation covered in the Biosimilars Market report?

Ans: The Types covered in the Biosimilars Market report are Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), Recombinant Glycosylated Proteins

1 Biosimilars Market Overview
1.1 Product Overview and Scope of Biosimilars
1.2 Biosimilars Segment by Type
1.2.1 Global Biosimilars Market Value Comparison by Type (2024-2030)
1.2.2 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
1.2.3 Recombinant Glycosylated Proteins
1.3 Biosimilars Segment by Application
1.3.1 Global Biosimilars Market Value by Application: (2024-2030)
1.3.2 Oncology
1.3.3 Blood Disorders
1.3.4 Growth Hormonal Deficiency
1.3.5 Chronic and Autoimmune Disorders
1.3.6 Others
1.4 Global Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Biosimilars Revenue 2019-2030
1.4.2 Global Biosimilars Sales 2019-2030
1.4.3 Global Biosimilars Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Biosimilars Market Competition by Manufacturers
2.1 Global Biosimilars Sales Market Share by Manufacturers (2019-2024)
2.2 Global Biosimilars Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Biosimilars Average Price by Manufacturers (2019-2024)
2.4 Global Biosimilars Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biosimilars, Product Type & Application
2.7 Biosimilars Market Competitive Situation and Trends
2.7.1 Biosimilars Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Biosimilars Players Market Share by Revenue
2.7.3 Global Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biosimilars Retrospective Market Scenario by Region
3.1 Global Biosimilars Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Biosimilars Global Biosimilars Sales by Region: 2019-2030
3.2.1 Global Biosimilars Sales by Region: 2019-2024
3.2.2 Global Biosimilars Sales by Region: 2025-2030
3.3 Global Biosimilars Global Biosimilars Revenue by Region: 2019-2030
3.3.1 Global Biosimilars Revenue by Region: 2019-2024
3.3.2 Global Biosimilars Revenue by Region: 2025-2030
3.4 North America Biosimilars Market Facts & Figures by Country
3.4.1 North America Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Biosimilars Sales by Country (2019-2030)
3.4.3 North America Biosimilars Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Biosimilars Market Facts & Figures by Country
3.5.1 Europe Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Biosimilars Sales by Country (2019-2030)
3.5.3 Europe Biosimilars Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biosimilars Market Facts & Figures by Country
3.6.1 Asia Pacific Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Biosimilars Sales by Country (2019-2030)
3.6.3 Asia Pacific Biosimilars Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Biosimilars Sales by Country (2019-2030)
3.7.3 Latin America Biosimilars Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Biosimilars Sales by Country (2019-2030)
3.8.3 Middle East and Africa Biosimilars Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biosimilars Sales by Type (2019-2030)
4.1.1 Global Biosimilars Sales by Type (2019-2024)
4.1.2 Global Biosimilars Sales by Type (2025-2030)
4.1.3 Global Biosimilars Sales Market Share by Type (2019-2030)
4.2 Global Biosimilars Revenue by Type (2019-2030)
4.2.1 Global Biosimilars Revenue by Type (2019-2024)
4.2.2 Global Biosimilars Revenue by Type (2025-2030)
4.2.3 Global Biosimilars Revenue Market Share by Type (2019-2030)
4.3 Global Biosimilars Price by Type (2019-2030)
5 Segment by Application
5.1 Global Biosimilars Sales by Application (2019-2030)
5.1.1 Global Biosimilars Sales by Application (2019-2024)
5.1.2 Global Biosimilars Sales by Application (2025-2030)
5.1.3 Global Biosimilars Sales Market Share by Application (2019-2030)
5.2 Global Biosimilars Revenue by Application (2019-2030)
5.2.1 Global Biosimilars Revenue by Application (2019-2024)
5.2.2 Global Biosimilars Revenue by Application (2025-2030)
5.2.3 Global Biosimilars Revenue Market Share by Application (2019-2030)
5.3 Global Biosimilars Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Biosimilars Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novartis Biosimilars Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Biocon
6.3.1 Biocon Corporation Information
6.3.2 Biocon Description and Business Overview
6.3.3 Biocon Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Biocon Biosimilars Product Portfolio
6.3.5 Biocon Recent Developments/Updates
6.4 Biogen
6.4.1 Biogen Corporation Information
6.4.2 Biogen Description and Business Overview
6.4.3 Biogen Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biogen Biosimilars Product Portfolio
6.4.5 Biogen Recent Developments/Updates
6.5 Fresenius Kabi AG
6.5.1 Fresenius Kabi AG Corporation Information
6.5.2 Fresenius Kabi AG Description and Business Overview
6.5.3 Fresenius Kabi AG Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Fresenius Kabi AG Biosimilars Product Portfolio
6.5.5 Fresenius Kabi AG Recent Developments/Updates
6.6 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Corporation Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Boehringer Ingelheim Biosimilars Product Portfolio
6.6.5 Boehringer Ingelheim Recent Developments/Updates
6.7 Merck KgaA
6.6.1 Merck KgaA Corporation Information
6.6.2 Merck KgaA Description and Business Overview
6.6.3 Merck KgaA Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck KgaA Biosimilars Product Portfolio
6.7.5 Merck KgaA Recent Developments/Updates
6.8 Mylan
6.8.1 Mylan Corporation Information
6.8.2 Mylan Description and Business Overview
6.8.3 Mylan Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Mylan Biosimilars Product Portfolio
6.8.5 Mylan Recent Developments/Updates
6.9 Eli Lilly
6.9.1 Eli Lilly Corporation Information
6.9.2 Eli Lilly Description and Business Overview
6.9.3 Eli Lilly Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Eli Lilly Biosimilars Product Portfolio
6.9.5 Eli Lilly Recent Developments/Updates
6.10 Teva Pharmaceutical
6.10.1 Teva Pharmaceutical Corporation Information
6.10.2 Teva Pharmaceutical Description and Business Overview
6.10.3 Teva Pharmaceutical Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Teva Pharmaceutical Biosimilars Product Portfolio
6.10.5 Teva Pharmaceutical Recent Developments/Updates
6.11 Dr. Reddy's Laboratories
6.11.1 Dr. Reddy's Laboratories Corporation Information
6.11.2 Dr. Reddy's Laboratories Biosimilars Description and Business Overview
6.11.3 Dr. Reddy's Laboratories Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Dr. Reddy's Laboratories Biosimilars Product Portfolio
6.11.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.12 Amgen
6.12.1 Amgen Corporation Information
6.12.2 Amgen Biosimilars Description and Business Overview
6.12.3 Amgen Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Amgen Biosimilars Product Portfolio
6.12.5 Amgen Recent Developments/Updates
6.13 Celltrion
6.13.1 Celltrion Corporation Information
6.13.2 Celltrion Biosimilars Description and Business Overview
6.13.3 Celltrion Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Celltrion Biosimilars Product Portfolio
6.13.5 Celltrion Recent Developments/Updates
6.14 Samsung Biologics
6.14.1 Samsung Biologics Corporation Information
6.14.2 Samsung Biologics Biosimilars Description and Business Overview
6.14.3 Samsung Biologics Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Samsung Biologics Biosimilars Product Portfolio
6.14.5 Samsung Biologics Recent Developments/Updates
6.15 Roche
6.15.1 Roche Corporation Information
6.15.2 Roche Biosimilars Description and Business Overview
6.15.3 Roche Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Roche Biosimilars Product Portfolio
6.15.5 Roche Recent Developments/Updates
6.16 Probiomed
6.16.1 Probiomed Corporation Information
6.16.2 Probiomed Biosimilars Description and Business Overview
6.16.3 Probiomed Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Probiomed Biosimilars Product Portfolio
6.16.5 Probiomed Recent Developments/Updates
6.17 Apotex
6.17.1 Apotex Corporation Information
6.17.2 Apotex Biosimilars Description and Business Overview
6.17.3 Apotex Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Apotex Biosimilars Product Portfolio
6.17.5 Apotex Recent Developments/Updates
6.18 Chong Kun Dang
6.18.1 Chong Kun Dang Corporation Information
6.18.2 Chong Kun Dang Biosimilars Description and Business Overview
6.18.3 Chong Kun Dang Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Chong Kun Dang Biosimilars Product Portfolio
6.18.5 Chong Kun Dang Recent Developments/Updates
6.19 JCR Pharmaceuticals
6.19.1 JCR Pharmaceuticals Corporation Information
6.19.2 JCR Pharmaceuticals Biosimilars Description and Business Overview
6.19.3 JCR Pharmaceuticals Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.19.4 JCR Pharmaceuticals Biosimilars Product Portfolio
6.19.5 JCR Pharmaceuticals Recent Developments/Updates
6.20 Gan & Lee Pharmaceuticals
6.20.1 Gan & Lee Pharmaceuticals Corporation Information
6.20.2 Gan & Lee Pharmaceuticals Biosimilars Description and Business Overview
6.20.3 Gan & Lee Pharmaceuticals Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Gan & Lee Pharmaceuticals Biosimilars Product Portfolio
6.20.5 Gan & Lee Pharmaceuticals Recent Developments/Updates
6.21 Gedeon Richter
6.21.1 Gedeon Richter Corporation Information
6.21.2 Gedeon Richter Biosimilars Description and Business Overview
6.21.3 Gedeon Richter Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Gedeon Richter Biosimilars Product Portfolio
6.21.5 Gedeon Richter Recent Developments/Updates
6.22 Biocad
6.22.1 Biocad Corporation Information
6.22.2 Biocad Biosimilars Description and Business Overview
6.22.3 Biocad Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Biocad Biosimilars Product Portfolio
6.22.5 Biocad Recent Developments/Updates
6.23 Coherus Bioscience
6.23.1 Coherus Bioscience Corporation Information
6.23.2 Coherus Bioscience Biosimilars Description and Business Overview
6.23.3 Coherus Bioscience Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.23.4 Coherus Bioscience Biosimilars Product Portfolio
6.23.5 Coherus Bioscience Recent Developments/Updates
6.24 Stada Arzneimittel AG
6.24.1 Stada Arzneimittel AG Corporation Information
6.24.2 Stada Arzneimittel AG Biosimilars Description and Business Overview
6.24.3 Stada Arzneimittel AG Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.24.4 Stada Arzneimittel AG Biosimilars Product Portfolio
6.24.5 Stada Arzneimittel AG Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biosimilars Industry Chain Analysis
7.2 Biosimilars Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biosimilars Production Mode & Process
7.4 Biosimilars Sales and Marketing
7.4.1 Biosimilars Sales Channels
7.4.2 Biosimilars Distributors
7.5 Biosimilars Customers
8 Biosimilars Market Dynamics
8.1 Biosimilars Industry Trends
8.2 Biosimilars Market Drivers
8.3 Biosimilars Market Challenges
8.4 Biosimilars Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
    Table 1. Global Biosimilars Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Biosimilars Market Value Comparison by Application (2024-2030) & (US$ Million)
    Table 3. Global Biosimilars Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Biosimilars Sales (K Units) of Key Manufacturers (2019-2024)
    Table 5. Global Biosimilars Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Biosimilars Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Biosimilars Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Biosimilars Average Price (USD/Unit) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Biosimilars, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Biosimilars, Product Type & Application
    Table 12. Global Key Manufacturers of Biosimilars, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Biosimilars Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Biosimilars Sales by Region (2019-2024) & (K Units)
    Table 18. Global Biosimilars Sales Market Share by Region (2019-2024)
    Table 19. Global Biosimilars Sales by Region (2025-2030) & (K Units)
    Table 20. Global Biosimilars Sales Market Share by Region (2025-2030)
    Table 21. Global Biosimilars Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Biosimilars Revenue Market Share by Region (2019-2024)
    Table 23. Global Biosimilars Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Biosimilars Revenue Market Share by Region (2025-2030)
    Table 25. North America Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Biosimilars Sales by Country (2019-2024) & (K Units)
    Table 27. North America Biosimilars Sales by Country (2025-2030) & (K Units)
    Table 28. North America Biosimilars Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Biosimilars Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Biosimilars Sales by Country (2019-2024) & (K Units)
    Table 32. Europe Biosimilars Sales by Country (2025-2030) & (K Units)
    Table 33. Europe Biosimilars Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Biosimilars Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Biosimilars Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Biosimilars Sales by Region (2019-2024) & (K Units)
    Table 37. Asia Pacific Biosimilars Sales by Region (2025-2030) & (K Units)
    Table 38. Asia Pacific Biosimilars Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Biosimilars Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Biosimilars Sales by Country (2019-2024) & (K Units)
    Table 42. Latin America Biosimilars Sales by Country (2025-2030) & (K Units)
    Table 43. Latin America Biosimilars Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Biosimilars Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Biosimilars Sales by Country (2019-2024) & (K Units)
    Table 47. Middle East & Africa Biosimilars Sales by Country (2025-2030) & (K Units)
    Table 48. Middle East & Africa Biosimilars Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Biosimilars Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Biosimilars Sales (K Units) by Type (2019-2024)
    Table 51. Global Biosimilars Sales (K Units) by Type (2025-2030)
    Table 52. Global Biosimilars Sales Market Share by Type (2019-2024)
    Table 53. Global Biosimilars Sales Market Share by Type (2025-2030)
    Table 54. Global Biosimilars Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Biosimilars Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Biosimilars Revenue Market Share by Type (2019-2024)
    Table 57. Global Biosimilars Revenue Market Share by Type (2025-2030)
    Table 58. Global Biosimilars Price (USD/Unit) by Type (2019-2024)
    Table 59. Global Biosimilars Price (USD/Unit) by Type (2025-2030)
    Table 60. Global Biosimilars Sales (K Units) by Application (2019-2024)
    Table 61. Global Biosimilars Sales (K Units) by Application (2025-2030)
    Table 62. Global Biosimilars Sales Market Share by Application (2019-2024)
    Table 63. Global Biosimilars Sales Market Share by Application (2025-2030)
    Table 64. Global Biosimilars Revenue (US$ Million) by Application (2019-2024)
    Table 65. Global Biosimilars Revenue (US$ Million) by Application (2025-2030)
    Table 66. Global Biosimilars Revenue Market Share by Application (2019-2024)
    Table 67. Global Biosimilars Revenue Market Share by Application (2025-2030)
    Table 68. Global Biosimilars Price (USD/Unit) by Application (2019-2024)
    Table 69. Global Biosimilars Price (USD/Unit) by Application (2025-2030)
    Table 70. Pfizer Corporation Information
    Table 71. Pfizer Description and Business Overview
    Table 72. Pfizer Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 73. Pfizer Biosimilars Product
    Table 74. Pfizer Recent Developments/Updates
    Table 75. Novartis Corporation Information
    Table 76. Novartis Description and Business Overview
    Table 77. Novartis Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 78. Novartis Biosimilars Product
    Table 79. Novartis Recent Developments/Updates
    Table 80. Biocon Corporation Information
    Table 81. Biocon Description and Business Overview
    Table 82. Biocon Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 83. Biocon Biosimilars Product
    Table 84. Biocon Recent Developments/Updates
    Table 85. Biogen Corporation Information
    Table 86. Biogen Description and Business Overview
    Table 87. Biogen Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 88. Biogen Biosimilars Product
    Table 89. Biogen Recent Developments/Updates
    Table 90. Fresenius Kabi AG Corporation Information
    Table 91. Fresenius Kabi AG Description and Business Overview
    Table 92. Fresenius Kabi AG Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 93. Fresenius Kabi AG Biosimilars Product
    Table 94. Fresenius Kabi AG Recent Developments/Updates
    Table 95. Boehringer Ingelheim Corporation Information
    Table 96. Boehringer Ingelheim Description and Business Overview
    Table 97. Boehringer Ingelheim Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 98. Boehringer Ingelheim Biosimilars Product
    Table 99. Boehringer Ingelheim Recent Developments/Updates
    Table 100. Merck KgaA Corporation Information
    Table 101. Merck KgaA Description and Business Overview
    Table 102. Merck KgaA Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 103. Merck KgaA Biosimilars Product
    Table 104. Merck KgaA Recent Developments/Updates
    Table 105. Mylan Corporation Information
    Table 106. Mylan Description and Business Overview
    Table 107. Mylan Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 108. Mylan Biosimilars Product
    Table 109. Mylan Recent Developments/Updates
    Table 110. Eli Lilly Corporation Information
    Table 111. Eli Lilly Description and Business Overview
    Table 112. Eli Lilly Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 113. Eli Lilly Biosimilars Product
    Table 114. Eli Lilly Recent Developments/Updates
    Table 115. Teva Pharmaceutical Corporation Information
    Table 116. Teva Pharmaceutical Description and Business Overview
    Table 117. Teva Pharmaceutical Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 118. Teva Pharmaceutical Biosimilars Product
    Table 119. Teva Pharmaceutical Recent Developments/Updates
    Table 120. Dr. Reddy's Laboratories Corporation Information
    Table 121. Dr. Reddy's Laboratories Description and Business Overview
    Table 122. Dr. Reddy's Laboratories Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 123. Dr. Reddy's Laboratories Biosimilars Product
    Table 124. Dr. Reddy's Laboratories Recent Developments/Updates
    Table 125. Amgen Corporation Information
    Table 126. Amgen Description and Business Overview
    Table 127. Amgen Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 128. Amgen Biosimilars Product
    Table 129. Amgen Recent Developments/Updates
    Table 130. Celltrion Corporation Information
    Table 131. Celltrion Description and Business Overview
    Table 132. Celltrion Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 133. Celltrion Biosimilars Product
    Table 134. Celltrion Recent Developments/Updates
    Table 135. Samsung Biologics Corporation Information
    Table 136. Samsung Biologics Description and Business Overview
    Table 137. Samsung Biologics Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 138. Samsung Biologics Biosimilars Product
    Table 139. Samsung Biologics Recent Developments/Updates
    Table 140. Roche Corporation Information
    Table 141. Roche Description and Business Overview
    Table 142. Roche Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 143. Roche Biosimilars Product
    Table 144. Roche Recent Developments/Updates
    Table 145. Probiomed Corporation Information
    Table 146. Probiomed Description and Business Overview
    Table 147. Probiomed Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 148. Probiomed Biosimilars Product
    Table 149. Probiomed Recent Developments/Updates
    Table 150. Apotex Corporation Information
    Table 151. Apotex Description and Business Overview
    Table 152. Apotex Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 153. Apotex Biosimilars Product
    Table 154. Apotex Recent Developments/Updates
    Table 155. Chong Kun Dang Corporation Information
    Table 156. Chong Kun Dang Description and Business Overview
    Table 157. Chong Kun Dang Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 158. Chong Kun Dang Biosimilars Product
    Table 159. Chong Kun Dang Recent Developments/Updates
    Table 160. JCR Pharmaceuticals Corporation Information
    Table 161. JCR Pharmaceuticals Description and Business Overview
    Table 162. JCR Pharmaceuticals Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 163. JCR Pharmaceuticals Biosimilars Product
    Table 164. JCR Pharmaceuticals Recent Developments/Updates
    Table 165. Gan & Lee Pharmaceuticals Corporation Information
    Table 166. Gan & Lee Pharmaceuticals Description and Business Overview
    Table 167. Gan & Lee Pharmaceuticals Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 168. Gan & Lee Pharmaceuticals Biosimilars Product
    Table 169. Gan & Lee Pharmaceuticals Recent Developments/Updates
    Table 170. Gedeon Richter Corporation Information
    Table 171. Gedeon Richter Description and Business Overview
    Table 172. Gedeon Richter Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 173. Gedeon Richter Biosimilars Product
    Table 174. Gedeon Richter Recent Developments/Updates
    Table 175. Biocad Corporation Information
    Table 176. Biocad Description and Business Overview
    Table 177. Biocad Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 178. Biocad Biosimilars Product
    Table 179. Biocad Recent Developments/Updates
    Table 180. Coherus Bioscience Corporation Information
    Table 181. Coherus Bioscience Description and Business Overview
    Table 182. Coherus Bioscience Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 183. Coherus Bioscience Biosimilars Product
    Table 184. Coherus Bioscience Recent Developments/Updates
    Table 185. Stada Arzneimittel AG Corporation Information
    Table 186. Stada Arzneimittel AG Description and Business Overview
    Table 187. Stada Arzneimittel AG Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 188. Stada Arzneimittel AG Biosimilars Product
    Table 189. Stada Arzneimittel AG Recent Developments/Updates
    Table 190. Key Raw Materials Lists
    Table 191. Raw Materials Key Suppliers Lists
    Table 192. Biosimilars Distributors List
    Table 193. Biosimilars Customers List
    Table 194. Biosimilars Market Trends
    Table 195. Biosimilars Market Drivers
    Table 196. Biosimilars Market Challenges
    Table 197. Biosimilars Market Restraints
    Table 198. Research Programs/Design for This Report
    Table 199. Key Data Information from Secondary Sources
    Table 200. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Biosimilars
    Figure 2. Global Biosimilars Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Biosimilars Market Share by Type in 2023 & 2030
    Figure 4. Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon) Product Picture
    Figure 5. Recombinant Glycosylated Proteins Product Picture
    Figure 6. Global Biosimilars Market Value Comparison by Application (2024-2030) & (US$ Million)
    Figure 7. Global Biosimilars Market Share by Application in 2023 & 2030
    Figure 8. Oncology
    Figure 9. Blood Disorders
    Figure 10. Growth Hormonal Deficiency
    Figure 11. Chronic and Autoimmune Disorders
    Figure 12. Others
    Figure 13. Global Biosimilars Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 14. Global Biosimilars Market Size (2019-2030) & (US$ Million)
    Figure 15. Global Biosimilars Sales (2019-2030) & (K Units)
    Figure 16. Global Biosimilars Average Price (USD/Unit) & (2019-2030)
    Figure 17. Biosimilars Report Years Considered
    Figure 18. Biosimilars Sales Share by Manufacturers in 2023
    Figure 19. Global Biosimilars Revenue Share by Manufacturers in 2023
    Figure 20. The Global 5 and 10 Largest Biosimilars Players: Market Share by Revenue in 2023
    Figure 21. Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 22. Global Biosimilars Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 23. North America Biosimilars Sales Market Share by Country (2019-2030)
    Figure 24. North America Biosimilars Revenue Market Share by Country (2019-2030)
    Figure 25. U.S. Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 26. Canada Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 27. Europe Biosimilars Sales Market Share by Country (2019-2030)
    Figure 28. Europe Biosimilars Revenue Market Share by Country (2019-2030)
    Figure 29. Germany Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 30. France Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 31. U.K. Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 32. Italy Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 33. Russia Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 34. Asia Pacific Biosimilars Sales Market Share by Region (2019-2030)
    Figure 35. Asia Pacific Biosimilars Revenue Market Share by Region (2019-2030)
    Figure 36. China Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 37. Japan Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 38. South Korea Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. India Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. Australia Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. China Taiwan Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 42. Indonesia Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 43. Thailand Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 44. Malaysia Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 45. Latin America Biosimilars Sales Market Share by Country (2019-2030)
    Figure 46. Latin America Biosimilars Revenue Market Share by Country (2019-2030)
    Figure 47. Mexico Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 48. Brazil Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 49. Argentina Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 50. Middle East & Africa Biosimilars Sales Market Share by Country (2019-2030)
    Figure 51. Middle East & Africa Biosimilars Revenue Market Share by Country (2019-2030)
    Figure 52. Turkey Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 53. Saudi Arabia Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 54. UAE Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 55. Global Sales Market Share of Biosimilars by Type (2019-2030)
    Figure 56. Global Revenue Market Share of Biosimilars by Type (2019-2030)
    Figure 57. Global Biosimilars Price (USD/Unit) by Type (2019-2030)
    Figure 58. Global Sales Market Share of Biosimilars by Application (2019-2030)
    Figure 59. Global Revenue Market Share of Biosimilars by Application (2019-2030)
    Figure 60. Global Biosimilars Price (USD/Unit) by Application (2019-2030)
    Figure 61. Biosimilars Value Chain
    Figure 62. Biosimilars Production Process
    Figure 63. Channels of Distribution (Direct Vs Distribution)
    Figure 64. Distributors Profiles
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS